Filip M, Papla I
Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Kraków.
Pol J Pharmacol. 2001 Nov-Dec;53(6):577-85.
It is established that dopamine (DA) neurotransmission plays a critical role in the behavioral (e.g. discriminative stimulus) effects of cocaine in rodents. Nonetheless, research has also demonstrated that reciprocal signaling between DA and monoamine neurotransmitters, i.e. serotonin (5-HT) and norepinephrine (NE) has important implication for understanding the actions of cocaine. The present study was focussed on the ability of novel antidepressant drugs (milnacipram, reboxetine and venlafaxine), which affect either NE or both 5-HT and NE reuptake mechanism, to alter (enhance or antagonize) the discriminative stimulus effects of cocaine. Moreover, we investigated if the combined treatment with those drugs and a DA D3 receptor agonist (pramipexole) could reproduce cocaine discrimination. Male Wistar rats were trained to discriminate cocaine (10 mg/kg, ip) from saline (ip) in a two-choice, water-reinforced fixed-ratio 20 drug discrimination paradigm. Given alone, none of antidepressant drugs induced substitution for the cocaine-lever responses. Pramipexole (0.25 mg/kg) produced a partial substitution for cocaine (i.e. 43-52% cocaine-lever responding). In combination experiments, milnacipram (10 mg/kg) or reboxetine (10 mg/kg) given with submaximal doses of cocaine (1.25-5 mg/kg) did not affect the cocaine dose-response curve or its ED50 values. Venlafaxine (10 mg/kg) given in combination with submaximal doses of cocaine (0.6-5 mg/kg) produced significant enhancement of cocaine discrimination with a leftward shift in the cocaine dose-response curve and a decrease in its ED50 value. Pretreatment with either milnacipram (10 mg/kg) or reboxetine (10 mg/kg) failed to modulate the partial substitution evoked by pramipexole (0.25 mg/kg). On the other hand, venlafaxine (10 mg/kg) given in combination with a submaximal dose of pramipexole (0.25 mg/kg), which separately elicited 16 and 42% the cocaine-lever responses, produced significant enhancement of cocaine discrimination (up to 99% of the drug-lever responding). These results indicate that the discriminative stimulus effects of cocaine in rats can be enhanced by venlafaxine or mimicked by the combination with this antidepressant drug and the DA D3 receptor agonist. This finding, together with the recent data reporting the lack of rewarding properties of venlafaxine and the attenuation of morphine dependence and withdrwal signs in rats by the drug, may indicate a possible therapeutic use of this antidepressant in cocaine abuse.
已证实多巴胺(DA)神经传递在可卡因对啮齿动物的行为(如辨别刺激)效应中起关键作用。尽管如此,研究也表明DA与单胺神经递质(即5-羟色胺(5-HT)和去甲肾上腺素(NE))之间的相互信号传导对于理解可卡因的作用具有重要意义。本研究聚焦于新型抗抑郁药(米那普明、瑞波西汀和文拉法辛)改变(增强或拮抗)可卡因辨别刺激效应的能力,这些药物影响NE或5-HT和NE的再摄取机制。此外,我们研究了这些药物与DA D3受体激动剂(普拉克索)联合治疗是否能重现可卡因辨别。雄性Wistar大鼠在双选、水强化固定比率20药物辨别范式中接受训练,以区分可卡因(10mg/kg,腹腔注射)和生理盐水(腹腔注射)。单独给予时,没有一种抗抑郁药能替代可卡因杠杆反应。普拉克索(0.25mg/kg)部分替代了可卡因(即43%-52%的可卡因杠杆反应)。在联合实验中,米那普明(10mg/kg)或瑞波西汀(10mg/kg)与次最大剂量的可卡因(1.25-5mg/kg)联合使用时,并未影响可卡因剂量反应曲线或其半数有效剂量(ED50)值。文拉法辛(10mg/kg)与次最大剂量的可卡因(0.6-5mg/kg)联合使用时,显著增强了可卡因辨别能力,可卡因剂量反应曲线向左移动,ED50值降低。米那普明(10mg/kg)或瑞波西汀(10mg/kg)预处理未能调节普拉克索(0.25mg/kg)引起的部分替代反应。另一方面,文拉法辛(10mg/kg)与次最大剂量的普拉克索(0.25mg/kg)联合使用,单独使用时分别引起16%和42%的可卡因杠杆反应,显著增强了可卡因辨别能力(高达99%的药物杠杆反应)。这些结果表明,文拉法辛可增强大鼠对可卡因的辨别刺激效应,或与这种抗抑郁药和DA D3受体激动剂联合使用可模拟该效应。这一发现,连同最近报道文拉法辛缺乏奖赏特性以及该药物可减轻大鼠吗啡依赖性和戒断症状的数据,可能表明这种抗抑郁药在可卡因滥用方面可能具有治疗用途。